From: Clinical significance of FBXW7 loss of function in human cancers
RNA type | ncRNA | Research subject | FBXW7 expression | Results or effects of the research | References |
---|---|---|---|---|---|
miRNAs | miR-18b-3p | Hepatic fibrosis | down-regulated | Promote liver fibrosis, promote tumor proliferation, and promote inflammation | [41] |
miR-23a | Colorectal cancer | down-regulated | Promote malignant transformation of colorectal cancer | [42] | |
miR-25 | Hepatocellular Carcinoma | down-regulated | Invasion and migration | [43] | |
miR-25 | Prostatic Small Cell Neuroendocrine Carcinoma | down-regulated | Upregulate AURKA, promote tumor proliferation | [44] | |
miR-27a | Bronchial epithelial cell carcinoma | down-regulated | Malignant transformation induced by the viral oncoprotein ST | [45] | |
miR-27b-3p | Multiple myeloma | down-regulated | Mcl-1 is upregulated and produces apoptosis resistance | [46] | |
miR-32 | Breast cancer | down-regulated | Inhibits apoptosis and promotes proliferation and migration of breast cancer cells. | [47] | |
miR-92a | Cervical Cancer | down-regulated | Promote proliferation of cervical cancer cells | [48] | |
miR-92a-3p | Colorectal cancer | down-regulated | Activation of Wnt/β-catenin pathway promotes cell stemness, EMT, metastasis and 5-FU/L-OHP resistance in CRC | [39] | |
miR-92a-3p | Gastric cancer | down-regulated | Promote invasive migration of gastric cancer | [49] | |
miR-92a-3p | Hepatocellular carcinoma | down-regulated | Promotes proliferation and cell cycle transition from G1 to S phase, and inhibits apoptosis in HCC cells | [40] | |
miR-101 | Bone marrow mesenchymal stem cell | down-regulated | Upregulate HIF1α | [50] | |
miR-144 | Nasopharyngeal carcinoma | down-regulated | Upregulate HIF1α | [51] | |
miR-155 | Glioma | down-regulated | Enhance the tumor cell viability | [52] | |
miR-155-3p | Hepatocellular carcinoma | down-regulated | Promote HCC cell proliferation | [53] | |
miR-182 | Breast cancer | down-regulated | Upregulate the HIF-1α-VEGF-A axis and promotes tumor invasion and migration | [54] | |
miR-182 | Colon adenoma | down-regulated | Induced transformation of adenoma to adenocarcinoma | [55] | |
miR-197-3p | Gastric cancer | down-regulated | Up-regulate cyclinD1, EMT, YAP1, down-regulate CCDC6 | [56] | |
miR-223 | Gastric cancer | down-regulated | Promote the cisplatin resistance; reduces trastuzumab sensitivity | ||
miR-223 | Oesophageal squamous cell carcinoma | down-regulated | Intervention of poor patient prognosis | [37] | |
miR-223 | Colorectal cancer | down-regulated | Increases endogenous cell cycle protein E protein and activity | [58] | |
miR-367 | Lung cancer | down-regulated | Promotes tumor cell invasion and migration and is associated with poor prognosis | [59] | |
miR-367 | Hepatocellular carcinoma | down-regulated | Promote EMT | [60] | |
miR-500a-3p | Gastric cancer | down-regulated | Increase cisplatin resistance | [61] | |
miR-503 | Colon adenoma | down-regulated | Induced transformation of adenoma to adenocarcinoma | [55] | |
miR-586 | Lung cancer | down-regulated | Promote tumorigenesis | [62] | |
miR-5000-3p | Laryngocarcinoma | down-regulated | Promote the invasion and migration of laryngeal cancer cells | [63] | |
lncRNAs | lncRNA-CASC2 | Hepatocellular carcinoma | up-regulated | Inhibit EMT | [60] |
lncRNA-MALAT1 | Glioma | up-regulated | Suppresse tumor cell viability | [52] | |
lncRNA-MIF | Lung cancer | up-regulated | Inhibit cMyc, inhibits aerobic glycolysis and tumorigenesis | [62] | |
lncRNA-MIR22HG | Laryngocarcinoma | up-regulated | Inhibit the invasion and migration of laryngeal cancer cells | [63] | |
lncRNA-MT1JP | Gastric cancer | up-regulated | Inhibit invasive migration of gastric cancer | [49] | |
lncRNA-FRE1L4 | Gastric cancer | up-regulated | Inhibit prostate cancer progression | [49] | |
lncRNA-TTN-AS1 | Esophageal Squamous Cell Carcinoma | up-regulated | Competitive binding of miR-133b promotes the expression of transcription factor Snail1, leading to an EMT cascade response | [64] | |
circRNAs | hsa_circ_001988a | Gastric cancer | up-regulated | Up-regulate cyclinD1, EMT, YAP1, down-regulate CCDC6 | [56] |
circFBXW4 | Hepatic fibrosis | up-regulated | Inhibit liver fibrosis, inhibit tumor proliferation, anti-inflammatory | [41] | |
FBXW7-185aa | Glioma | - | Reduce the expression of c-Myc expression, associated with good patient survival | [65] | |
circ-FBXW7a | Colon adenoma | - | Decrease the expression of NEK2, mTOR and PTEN to induce tumor suppression | [66] |